Kolmar BioTech콜마바이오텍

Kolmar BioTech is loss-making on an operating basis over the last twelve months, while its share price has fallen over the past three months.

Kolmar BioTech reported trailing twelve-month revenue of ₩44.2B to H1 2026 with a small operating loss of ₩0.5B and a net profit of ₩1.2B, which the filings suggest may rely on non-operating items. Borrowings of ₩33.0B exceed cash of ₩15.7B, and free cash flow over the period was negative at -₩2.9B. The share price closed at ₩2,100 on 2026-10-27, down 13.9% over three months but up 14.9% over one year.

What stands out

• Annual revenue rose 11.9% in 2024 but fell 13% in 2025, and operating income swung from ₩1.8B in 2024 to a loss of ₩3.9B in 2025.
• Liabilities are 288.6% of equity, and borrowings are roughly twice cash, so balance-sheet leverage is a visible feature of the filings.
• Net income is positive over the trailing twelve months despite the operating loss, with a 2.8% net margin and 4.4% ROE.
• Valuation metrics show a P/E of 28.6 and P/B of 1.3, with no dividend, and the company does not appear in the data with analyst ratings or price targets.
• Recent filings are mainly corporate actions: a merger decision (amended in July), a merger completion report in September, and a conversion price adjustment in August. Foreign ownership is 8.1%, roughly unchanged over 60 days.

What to watch

• The next half-year or annual results, to see whether operating income turns sustainably positive and whether the net profit holds without operating support.
• Effects of the completed merger on the company's finances, share count and debt, which the data does not detail.
• Free cash flow and borrowing levels, since the data shows negative cash generation alongside debt above cash.